Table 3 Kaplan-Meier survival function analysis in glioblastoma patients (log-rank test)
From: MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma
Variable | n | Events | Survival (months) | |||
|---|---|---|---|---|---|---|
Median | 95% CI | P | ||||
MGMT promoter methylation | U | 37 | 37 | 6.2 | 4.6 to 7.9 | 0.005 |
M | 39 | 32 | 9.9 | 4.2 to 15.7 | ||
GATA6 promoter methylation | U | 24 | 20 | 9.6 | 7.2 to 11.9 | 0.208 |
M | 52 | 49 | 6.2 | 2.9 to 9.5 | ||
CD81 promoter methylation | U | 41 | 38 | 7.5 | 4.6 to 10.3 | 0.395 |
M | 35 | 31 | 8.9 | 4.6 to 13.3 | ||
DR4 promoter methylation | U | 44 | 40 | 8.9 | 4.9 to 12.8 | 0.174 |
M | 31 | 29 | 7.5 | 5.6 to 9.3 | ||
CASP8 promoter methylation | U | 33 | 29 | 9.9 | 6.9 to 12.9 | 0.040 |
M | 42 | 39 | 6.2 | 3.3 to 9.2 | ||